133.96
+1.20%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Axsome Therapeutics
From its filings with the US Securities and Exchange Commission
Axsome Therapeutics is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AXSM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $638.5m and a net loss of $183.2m. At that date it held total assets of $689.8m and shareholders' equity of $88.3m. By business, Product [Member] brought in 99.3% of revenue, followed by Royalty and Milestone Revenue [Member] at 0.7%.
We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes.
Our innovative CNS portfolio is anchored by three U.S. Food and Drug Administration (FDA) approved commercial products: AUVELITY® for the treatment of major depressive disorder (MDD), SUNOSI® for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO® for the acute treatment of migraine with or without aura in adults. Total revenues from our three commercial products totaled $638.5 million for 2025, representing 66% annual growth compared to 2024.
We are also advancing a deep pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Our lead product candidate, AXS-05 (dextromethorphan and bupropion), is currently being developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. In December 2025, the FDA accepted for filing the Company’s supplemental NDA (sNDA) for AXS-05 for the treatment of Alzheimer’s disease agitation. The application was granted Priority Review designation and a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026.
Quoted from its 10-K, filed 23 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Nov 2015
- Employees
- 925
- Website
- axsome.com ↗
- Head office
- ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Herriot TabuteauChairman of the Board, President, Chief Executive Officer, Founder, since 2012$10.4m
- Mr. Nick PizzieChief Financial Officer$3.8m
- Mr. Mark JacobsonChief Operating Officer$4.2m
- Mr. Hunter MurdockGeneral Counsel$3.2m
- Mr. Ari MaizelChief Commercial Officer$3.2m
- Dr. Mark ColemanLead Independent Director$432,791
- Dr. Roger JeffsIndependent Director$403,734
- Dr. Susan MahonyIndependent Director$398,310
- Mr. Mark SaadIndependent Director$408,593
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 15
- Environment
- 4
- Social
- 22
- Governance
- 18
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Axsome Therapeutics Inc has an impressive product pipeline that includes several innovative and potentially groundbreaking treatments. This provides a strong foundation for future growth and success in the pharmaceutical industry.
- The company is led by a highly experienced and skilled management team, with a track record of success in the healthcare sector. Their expertise and strategic vision contribute to Axsome's ability to effectively navigate the competitive landscape.
- Axsome's clinical trials have consistently demonstrated positive results, showing the efficacy and safety of their products. This not only boosts the confidence of investors and stakeholders but also contributes to gaining regulatory approvals more efficiently.
Weaknesses
- Despite the company's promising product pipeline, Axsome currently has a limited market presence. This could potentially pose challenges in terms of market penetration and obtaining widespread adoption of their products.
- Axsome's financial stability heavily relies on external funding sources, such as grants and partnerships. This dependence on external funding increases the vulnerability to market fluctuations and can pose obstacles to the company's plans for expansion and growth.
Opportunities
- The pharmaceutical industry is witnessing a growing demand for innovative treatments, particularly in areas with high unmet medical needs. Axsome has the opportunity to capture this potential market by successfully commercializing their innovative products.
- Axsome can explore strategic partnerships and collaborations with other pharmaceutical companies or research institutions. Such partnerships can provide access to additional resources, expertise, and distribution channels, facilitating faster market entry and expansion.
Threats
- The pharmaceutical industry is highly competitive, with numerous established companies and new entrants constantly vying for market share. Axsome faces the threat of competition from larger, more resourceful competitors who may have similar products or better market access.
- The regulatory landscape surrounding the pharmaceutical industry can be complex and stringent. Axsome might encounter challenges in obtaining necessary approvals from regulatory authorities, leading to potential delays or even rejection of their products.
- Axsome's success heavily relies on the protection of their intellectual property rights. The company faces the risk of patent infringement and intellectual property theft, which could negatively impact their ability to generate revenue and maintain a competitive advantage.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.